B. Rogala, M. Kupczyk, G. Bochenek, P. Śliwiński, M. Moniuszko, J. Glück, R. Dobek, M. Kulus
{"title":"哮喘的生物治疗——波兰过敏症学会(PTA)和波兰肺病学会(PTChP)立场声明","authors":"B. Rogala, M. Kupczyk, G. Bochenek, P. Śliwiński, M. Moniuszko, J. Glück, R. Dobek, M. Kulus","doi":"10.5114/pja.2020.96664","DOIUrl":null,"url":null,"abstract":"Biological therapy is the breakthrough in the management of spectrum of various diseases It also concerns asthma therapy The data regarding the role of biologics in the treatment strategy of severe asthma are presented The overview on how mediators of type 2 inflammation drives the pathology of the disease is given It justifies the biological treatment options approved The development of treatment strategy targeting non-type 2 inflammation is also highlighted The data regarding the risk and safety of biologics are discussed Document includes the featured rules of the classification of patients with severe asthma to this reliable and efficient therapy The outlook how to perceive the safety of biologics in the time of COVID-19 epidemic is also given","PeriodicalId":7469,"journal":{"name":"Alergologia Polska - Polish Journal of Allergology","volume":"1 1","pages":""},"PeriodicalIF":0.2000,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.5114/pja.2020.96664","citationCount":"1","resultStr":"{\"title\":\"Biological therapy of asthma – position statement of Polish Allergology Society (PTA) and Polish Society of Lung Diseases (PTChP)\",\"authors\":\"B. Rogala, M. Kupczyk, G. Bochenek, P. Śliwiński, M. Moniuszko, J. Glück, R. Dobek, M. Kulus\",\"doi\":\"10.5114/pja.2020.96664\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Biological therapy is the breakthrough in the management of spectrum of various diseases It also concerns asthma therapy The data regarding the role of biologics in the treatment strategy of severe asthma are presented The overview on how mediators of type 2 inflammation drives the pathology of the disease is given It justifies the biological treatment options approved The development of treatment strategy targeting non-type 2 inflammation is also highlighted The data regarding the risk and safety of biologics are discussed Document includes the featured rules of the classification of patients with severe asthma to this reliable and efficient therapy The outlook how to perceive the safety of biologics in the time of COVID-19 epidemic is also given\",\"PeriodicalId\":7469,\"journal\":{\"name\":\"Alergologia Polska - Polish Journal of Allergology\",\"volume\":\"1 1\",\"pages\":\"\"},\"PeriodicalIF\":0.2000,\"publicationDate\":\"2020-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.5114/pja.2020.96664\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Alergologia Polska - Polish Journal of Allergology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5114/pja.2020.96664\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"ALLERGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Alergologia Polska - Polish Journal of Allergology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5114/pja.2020.96664","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ALLERGY","Score":null,"Total":0}
Biological therapy of asthma – position statement of Polish Allergology Society (PTA) and Polish Society of Lung Diseases (PTChP)
Biological therapy is the breakthrough in the management of spectrum of various diseases It also concerns asthma therapy The data regarding the role of biologics in the treatment strategy of severe asthma are presented The overview on how mediators of type 2 inflammation drives the pathology of the disease is given It justifies the biological treatment options approved The development of treatment strategy targeting non-type 2 inflammation is also highlighted The data regarding the risk and safety of biologics are discussed Document includes the featured rules of the classification of patients with severe asthma to this reliable and efficient therapy The outlook how to perceive the safety of biologics in the time of COVID-19 epidemic is also given
期刊介绍：
Alergologia Polska - Polish Journal of Allergology is aimed mainly at allergologists, but also medical doctors working in related fields, such as otolaryngology, pulmonology, and dermatology. The main goal of the journal is to ensure rapid publication of important research papers and interesting case studies from the following areas: allergology, diagnostics, therapy of allergic diseases, in particular in the area of immunotherapy, rhinitis, asthma. The Editorial Board accepts for publication original papers, case studies and letters to the Editor. We also publish review articles (both commissioned and those agreed upon with the Editor-in-Chief), articles dealing with standards of medical practice, as well as special issues. The journal is published quarterly. We guarantee short review times (up to two weeks) and immediate publication on-line upon Editor acceptance.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
